SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001549595-23-000030
Filing Date
2023-04-13
Accepted
2023-04-13 16:02:43
Documents
13
Period of Report
2023-04-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20230413.htm   iXBRL 8-K 29434
2 EX-99.1 nrix-20230413xexx991.htm EX-99.1 73033
  Complete submission text file 0001549595-23-000030.txt   251587

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20230413.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20230413_lab.xml EX-101.LAB 26847
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20230413_pre.xml EX-101.PRE 14114
7 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20230413_htm.xml XML 4590
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 23818362
SIC: 2834 Pharmaceutical Preparations